About: Kateřina Machová Poláková

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Kateřina Machová Poláková Goto Sponge NotDistinct Permalink

An Entity of Type : wikibase:Item, within Data Space : wikidata.demo.openlinksw.com associated with source document(s)

researcher

Attributes	Values
rdf:type	Item
description	forskare (sv) researcher (en) 연구원 (ko) 研究者 (ja) wetenschapper (nl) дослідниця (uk) эрдэмтэн (mn) изилдөөчү (ky) 研究者 (zh) հետազոտող (hy) hulumtuese (sq) ricercatrice (it) ikertzaile txekiarra (eu) investigadora checa (es) investigadora checa (gl) investigadora checa (pt) investigadora checa (ast) investigadora txeca (ca) chercheuse tchèque (fr)
rdfs:label	Kateřina Machová Poláková (cs) Kateřina Machová Poláková (en) Kateřina Machová Poláková (es) Kateřina Machová Poláková (nl) Kateřina Machová Poláková (sl) Kateřina Machová Poláková (ast)
skos:prefLabel	Kateřina Machová Poláková (cs) Kateřina Machová Poláková (en) Kateřina Machová Poláková (es) Kateřina Machová Poláková (nl) Kateřina Machová Poláková (sl) Kateřina Machová Poláková (ast)
name	Kateřina Machová Poláková (cs) Kateřina Machová Poláková (en) Kateřina Machová Poláková (es) Kateřina Machová Poláková (nl) Kateřina Machová Poláková (sl) Kateřina Machová Poláková (ast)
Scopus author ID	wds:Q55283793-FBA3B9BA-C7BD-4B8D-A86A-045F2F69A6BC
Scopus author ID	26664803300
given name	wds:Q55283793-AE522DF7-8FB8-4600-8BC9-E5DF07F9AB8F
given name	Kateřina
described by source	wds:Q55283793-E4CE85F8-16BF-42E8-82F5-EC776FC10CCA
instance of	wds:Q55283793-F2658072-B148-43F1-A27A-74A1F4C87A70
NL CR AUT ID	wds:Q55283793-1a7e92a3-49af-1b42-1915-683390a929a6
described by source	Medvik
instance of	Homo sapiens
NL CR AUT ID	xx0139783
occupation	wds:Q55283793-4B4FD210-A958-4092-B175-15A2256BECEC
languages spoken, written or signed	wds:Q55283793-502F7F55-2DA1-40DC-B181-5DAB9BE4297C
birth name	wds:Q55283793-258A240E-5A13-4350-80B1-DB68CEC1250E
sex or gender	wds:Q55283793-6756116F-9E0A-44CD-A2BF-8D188E23CEDA
VIAF ID	wds:Q55283793-07052626-4edd-8b3c-034c-86fb040d2504
country of citizenship	wds:Q55283793-EC911E8A-67EC-428F-BC60-60B5ECA1219D
WorldCat Identities ID (superseded)	wds:Q55283793-24818B14-C5C9-4FF0-8302-4D09F3FE5D27
VIAF ID	http://viaf.org/viaf/183828355
occupation	researcher
languages spoken, written or signed	Czech
birth name	Kateřina Poláková (cs)
sex or gender	female organism
VIAF ID	183828355
country of citizenship	Czech Republic
WorldCat Identities ID (superseded)	viaf-183828355
ORCID iD	wds:Q55283793-A242CE86-E6DF-4F51-BB97-BAEF864DE557
ORCID iD	https://orcid.org/0000-0002-7398-5555
ORCID iD	0000-0002-7398-5555
married name	wds:Q55283793-7EEF7D19-69B0-445A-8119-EED666E87C74
married name	Kateřina Machová Poláková (cs)
ResearcherID	wds:Q55283793-ABC6DA2C-A9D6-4804-B7D7-AAB2DC6278BF
ResearcherID	G-5337-2017
is about of	https://www.wikidata.org/wiki/Special:EntityData/Q55283793
is author of	Assessment of adenosine triphosphate-binding cassette subfamily B member 1 (ABCB1) mRNA expression in patients with de novo chronic myelogenous leukemia: the role of different cell types. Expression patterns of microRNAs associated with CML phases and their disease related targets Unraveling the complexity of tyrosine kinase inhibitor-resistant populations by ultra-deep sequencing of the BCR-ABL kinase domain High-resolution melt curve analysis: initial screening for mutations in BCR-ABL kinase domain Laboratory recommendations for scoring deep molecular responses following treatment for chronic myeloid leukemia. Role of epigenetics in chronic myeloid leukemia Real-time PCR quantification of major Wilms' tumor gene 1 (WT1) isoforms in acute myeloid leukemia, their characteristic expression patterns and possible functional consequences. Imatinib as the first-line treatment of patients with chronic myeloid leukemia diagnosed in the chronic phase: can we compare real life data to the results from clinical trials? Efficacy and tolerance of dasatinib after imatinib failure or intolerance for patients with chronic myeloid leukemia treated in three different hospitals compare well with results achievable in formal clinical trials. Monitoring of childhood ALL using BCR-ABL1 genomic breakpoints identifies a subgroup with CML-like biology. Genotypes of SLC22A4 and SLC22A5 regulatory loci are predictive of the response of chronic myeloid leukemia patients to imatinib treatment AFLP-AFLP in silico-NGS approach reveals polymorphisms in repetitive elements in the malignant genome Current survival measures reliably reflect modern sequential treatment in CML: correlation with prognostic stratifications Development and evaluation of a secondary reference panel for BCR-ABL1 quantification on the International Scale BCR-ABL mutations in chronic myeloid leukemia–Not only detection Characterization of 46 patient-specific BCR-ABL1 fusions and detection of SNPs upstream and downstream the breakpoints in chronic myeloid leukemia using next generation sequencing. Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial. Next-generation sequencing for sensitive detection of BCR-ABL1 mutations relevant to tyrosine kinase inhibitor choice in imatinib-resistant patients Next-generation deep sequencing improves detection of BCR-ABL1 kinase domain mutations emerging under tyrosine kinase inhibitor treatment of chronic myeloid leukemia patients in chronic phase Somatic Mutations in Oncogenes Are in Chronic Myeloid Leukemia Acquired De Novo via Deregulated Base-Excision Repair and Alternative Non-Homologous End Joining The SNP rs460089 in the gene promoter of the drug transporter OCTN1 has prognostic value for treatment-free remission in chronic myeloid leukemia patients treated with imatinib Control genes in international standardization of real-time RT-PCR for BCR-ABL. Interferon-α Revisited: Individualized Treatment Management Eased the Selective Pressure of Tyrosine Kinase Inhibitors on BCR-ABL1 Mutations Resulting in a Molecular Response in High-Risk CML Patients Constant BCR-ABL transcript level >or=0.1% (IS) in patients with CML responding to imatinib with complete cytogenetic remission may indicate mutation analysis Expression of genes encoding centrosomal proteins and the humoral response against these proteins in chronic myeloid leukemia The predictive value of human organic cation transporter 1 and ABCB1 expression levels in different cell populations of patients with de novo chronic myelogenous leukemia Analysis of chronic myeloid leukaemia during deep molecular response by genomic PCR: a traffic light stratification model with impact on treatment-free remission Persistence of Drug-Resistant Leukemic Stem Cells and Impaired NK Cell Immunity in CML Patients Depend on MIR300 Antiproliferative and PP2A-Activating Functions Quantitative Analysis of Mutant Subclones in Chronic Myeloid Leukemia: Comparison of Different Methodological Approaches.

Faceted Search & Find service v1.16.117 as of May 05 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3239 as of May 5 2024, on Linux (x86_64-centos_6-linux-gnu), Single-Server Edition (378 GB total memory, 180 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software